UDR, Inc. (NYSE:UDR) Expected to Post Quarterly Sales of $296.61 Million

Share on StockTwits

Wall Street analysts expect that UDR, Inc. (NYSE:UDR) will post $296.61 million in sales for the current fiscal quarter, Zacks reports. Eight analysts have made estimates for UDR’s earnings. The highest sales estimate is $309.50 million and the lowest is $283.35 million. UDR posted sales of $264.73 million during the same quarter last year, which indicates a positive year over year growth rate of 12%. The business is expected to report its next quarterly earnings results on Tuesday, February 11th.

On average, analysts expect that UDR will report full year sales of $1.13 billion for the current year, with estimates ranging from $1.11 billion to $1.14 billion. For the next financial year, analysts anticipate that the firm will post sales of $1.22 billion, with estimates ranging from $1.16 billion to $1.30 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow UDR.

UDR (NYSE:UDR) last issued its earnings results on Tuesday, October 29th. The real estate investment trust reported $0.09 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.52 by ($0.43). UDR had a return on equity of 5.51% and a net margin of 15.20%. The company had revenue of $295.40 million during the quarter, compared to analysts’ expectations of $285.45 million. During the same period in the previous year, the company earned $0.07 EPS. UDR’s quarterly revenue was up 11.0% on a year-over-year basis.

Several equities research analysts recently issued reports on the stock. TheStreet downgraded shares of UDR from a “b-” rating to a “c+” rating in a research note on Friday, November 15th. Wells Fargo & Co raised their price objective on shares of UDR from $46.00 to $47.00 and gave the stock a “market perform” rating in a report on Tuesday, August 13th. Mizuho downgraded shares of UDR from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $52.00 to $50.00 in a research report on Thursday, November 7th. Barclays set a $52.00 target price on shares of UDR and gave the company a “hold” rating in a research note on Friday, October 11th. Finally, Capital One Financial upgraded UDR from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $45.00 to $50.00 in a research note on Monday, September 16th. Eight analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. UDR currently has a consensus rating of “Hold” and an average price target of $50.44.

In related news, SVP Harry G. Alcock sold 10,000 shares of the company’s stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $48.54, for a total transaction of $485,400.00. Following the completion of the transaction, the senior vice president now directly owns 87,284 shares in the company, valued at approximately $4,236,765.36. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Thomas W. Toomey sold 40,000 shares of the company’s stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $48.61, for a total value of $1,944,400.00. Following the transaction, the chief executive officer now owns 1,642,826 shares of the company’s stock, valued at $79,857,771.86. The disclosure for this sale can be found here. In the last three months, insiders sold 80,000 shares of company stock worth $3,885,200. Company insiders own 2.85% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP bought a new position in UDR in the 1st quarter worth about $157,000. Amundi Pioneer Asset Management Inc. raised its stake in UDR by 36.3% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 383,735 shares of the real estate investment trust’s stock valued at $17,445,000 after acquiring an additional 102,266 shares in the last quarter. 6 Meridian raised its stake in UDR by 2.0% during the 2nd quarter. 6 Meridian now owns 11,688 shares of the real estate investment trust’s stock valued at $525,000 after acquiring an additional 234 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its stake in UDR by 54.9% during the 2nd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 3,666 shares of the real estate investment trust’s stock valued at $165,000 after acquiring an additional 1,300 shares in the last quarter. Finally, OTA Financial Group L.P. acquired a new position in UDR during the 2nd quarter worth $590,000. Institutional investors and hedge funds own 96.12% of the company’s stock.

UDR stock traded down $1.27 during midday trading on Friday, hitting $46.78. 1,952,367 shares of the company were exchanged, compared to its average volume of 1,480,340. The company has a market cap of $14.08 billion, a PE ratio of 23.87, a price-to-earnings-growth ratio of 3.60 and a beta of 0.38. UDR has a fifty-two week low of $38.14 and a fifty-two week high of $50.61. The company’s fifty day moving average price is $48.65 and its 200-day moving average price is $47.11. The company has a debt-to-equity ratio of 1.22, a current ratio of 5.99 and a quick ratio of 5.99.

About UDR

UDR, Inc (NYSE: UDR), an S&P 500 company, is a leading multifamily real estate investment trust with a demonstrated performance history of delivering superior and dependable returns by successfully managing, buying, selling, developing and redeveloping attractive real estate properties in targeted U.S.

Further Reading: What is a Reverse Stock Split?

Get a free copy of the Zacks research report on UDR (UDR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for UDR (NYSE:UDR)

Receive News & Ratings for UDR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UDR and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.